MedTrace Logo

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

NCT03665675 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-15

No results posted yet for this study

Summary

This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus \[CMV\] specific cytotoxic T-lymphocytes \[CTLs\]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific \[AdV\] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.

Conditions

  • Allogeneic Hematopoietic Stem Cell Transplantation Recipient
  • Cytomegalovirus
  • Donor
  • Solid Organ Transplantation Recipient
  • Adenovirus

Interventions

BIOLOGICAL

Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes

Given intravenously

BIOLOGICAL

Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes

Given intravenously

Sponsors & Collaborators

  • Sumithira Vasu

    lead OTHER

Principal Investigators

  • Sumithira Vasu, MBBS · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-07
Primary Completion
2026-08-20
Completion
2026-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03665675 on ClinicalTrials.gov